Fig. 6

Irisin alleviates osteoporosis through the p38/MAPK pathway in vivo. (A-F) After completing the expected treatment with irisin and p38 inhibitors, we measured the level of the body weight (A), serum Ca²⁺ (B), serum 25 (OH) D (C), serum osteocalcin (D) and urinary DPD (E) in osteoporosis mice, and detected the weight of tibia and femur at 8th weeks (F). (G-L) After completing the expected treatment with irisin and p38 inhibitors, we isolated mouse BMSCs to detect the mRNA expression of Runx2 (G), OSX (H), OCN (I), OPN (J), ALP (K) and BMP2 (L) using RT-qPCR. 5 mice in each group. ***P < 0.001 compared with Healthy group; ^###P < 0.001 compared with OP group; ^&P < 0.05, ^&&P < 0.01 and ^&&&P < 0.001 compared with Irisin group. OP, osteoporosis mice. Irisin, osteoporosis mice treated with irisin. Irisin + SB, osteoporosis mice treated with irisin and p38 inhibitors (SB203580, SB)